HonCode

Go Back   HER2 Support Group Forums > General Cancer News
Reload this Page Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors
Register Gallery FAQ Members List Calendar Today's Posts

General Cancer News Latest Breast Cancer News from Moreover Technologies

Reply
 
Thread Tools Display Modes
Old 01-06-2009, 08:20 PM   #1
News
Senior Member
 
News's Avatar
 
Join Date: Oct 2007
Posts: 18,954
Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX ) today announced that it has acquired an option to license rights to SB1518, an orally available, potent, and selective inhibitor of Janus Kinase 2 (JAK2), and SB1578, also a JAK2 inhibitor, from S*BIO Pte Ltd based in Singapore.

More...
News is offline   Reply With Quote
Reply

« Previous Thread | Next Thread »

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -7. The time now is 01:19 PM.
Contact Us - HER2 Support Group - Archive - Privacy Statement - Top

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter